-transparent.png){kind=logo}
Three stable murine hybridoma cell lines, which secrete monoclonal antibodies (mAb) to human tumor necrosis factor alpha (TNF alpha), were established. None of the monoclonal antibodies cross-reacted with lymphotoxin, interleukin 2 (IL 2) or Interferon gamma (IFN gamma). The highly species-specific monoclonal antibody, designated as mAb 195, neutralizes the cytotoxic activity of human and chimpanzee TNF alpha. This antibody was further used during in vivo studies to neutralize human TNF alpha in a murine animal model. The mAb 114 is a weakly neutralizing antibody that binds to a different epitope of TNF alpha than mAb 195. mAb 114 shows a wide range of cross-reactivity with TNF alpha of the following species: dog, pig, cynomolgus, rhesus, baboon and chimpanzee. The mAb 199 binds to human TNF alpha, but does not neutralize the cytotoxic activity. The epitope recognized by this mAb is in close proximity to mAb 114. A reproducible, sensitive immunoassay for human TNF7 alpha has been developed using the antibodies mAb 199 and mAb 195. The test is performed within 6 hr and detects TNF7 alpha in serum samples, with a limit of detection of 5 to 10 pg/mL.
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
January 1992,
Anticancer research,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
January 1998,
Journal of drug targeting,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
April 1993,
Lymphokine and cytokine research,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
January 1991,
Chinese journal of biotechnology,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
July 1994,
Immunology letters,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
January 1987,
Journal of immunological methods,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
February 1994,
Archives of surgery (Chicago, Ill. : 1960),
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
November 2009,
P & T : a peer-reviewed journal for formulary management,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
July 1992,
[Hokkaido igaku zasshi] The Hokkaido journal of medical science,
A Möller, and
F Emling, and
D Blohm, and
E Schlick, and
K Schollmeier
February 2008,
Arthritis and rheumatism,
